Emergent BioSolutions
Emergent BioSolutions
Explore linked clinical trials.7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection | DNA Virus Infections, Infections, milker's nodule, smallpox, viral infectious disease | Enrolling by invitation | Not stated | 2026-05-12 | NCT01374984 | |
| Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax | Bacillaceae infectious disease, Bacterial Infections and Mycoses, Infections, anthrax infection, bacterial infectious disease, gram-positive bacterial infections | Not yet recruiting | Not stated | 2026-03-17 | NCT07478471 | |
| A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients | Bacillaceae infectious disease, Bacterial Infections and Mycoses, Infections, anthrax infection, bacterial infectious disease, gram-positive bacterial infections, inhalational anthrax | Not yet recruiting | Not stated | 2026-02-06 | NCT03569553 | |
| Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax | Bacillaceae infectious disease, Bacterial Infections and Mycoses, Infections, anthrax infection, bacterial infectious disease, gram-positive bacterial infections | Not yet recruiting | Not stated | 2026-02-06 | NCT03569514 | |
| Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario | Bacillaceae infectious disease, Bacterial Infections and Mycoses, Infections, anthrax infection, bacterial infectious disease, gram-positive bacterial infections | Not yet recruiting | Phase 4 | 2026-02-06 | NCT02177721 | |
| BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients | Bacterial Infections and Mycoses, Chemically-Induced Disorders, Clostridium infectious disease, Foodborne Diseases, Infections, bacterial infectious disease, botulism, gram-positive bacterial infections, nervous system disorder, neuromuscular disease, neuromuscular junction disease, poisoning, toxic encephalopathy | Enrolling by invitation | Phase 4 | 2026-01-16 | NCT02051062 | |
| Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease. | Bacillaceae infectious disease, Bacterial Infections and Mycoses, Infections, anthrax infection, bacterial infectious disease, cutaneous anthrax, gastrointestinal anthrax, gram-positive bacterial infections, inhalational anthrax | Not yet recruiting | Not stated | 2025-12-08 | NCT07268612 |